Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6281151 | Neuroscience Letters | 2015 | 5 Pages |
Abstract
Administration of RA at the dose of 8Â mg/kg did not alter cognitive function in control and scopolamine treated groups. The combination of anticholinesterase, neuroprotective, and antioxidant properties of RA may all be responsible for the observed effects. These results indicate the beneficial effects of subchronic RA administration in passive avoidance learning and memory in control rats as well as in a pharmacological model of cholinergic deficit which continue to expand the knowledge base in creating new treatment strategies for cognition deficits and dementia. Of course, further studies are warranted for clinical use of RA in the management of demented subjects.
Related Topics
Life Sciences
Neuroscience
Neuroscience (General)
Authors
Parisa Hasanein, Azam Kazemian Mahtaj,